The BioMed X Institute
19.12.2023 10:03:15 CET | ACCESS Newswire | Press release
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan. The project entitled "New Strategies to Engage Neutrophils in Solid Tumors" will be hosted by the BioMed X Institute in Heidelberg, Germany. The goal of this research project is to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.
Developing immunotherapies that target T cells has proved highly effective, and it is still a rapidly evolving research area. However, many patients remain resistant to these therapies, necessitating the development of novel immunological strategies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems to be paradoxical according to the data accumulated thus far. By uncovering novel neutrophil biology, this project aims to leverage their functions to design novel immunotherapies.
The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C03 before February 18, 2024.
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Oncology and immunology, including tumor immunology, are key areas of expertise at BioMed X. We are proud and honored that Ono has chosen our institute to develop new strategies for engaging neutrophils in cancer therapy".
Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono Pharmaceutical: "We are very pleased to form a partnership with BioMed X in our mission dedicated to overcoming cancer. This innovative research collaboration will engage us with highly talented scientists around the world who possess unique ideas for immunotherapy utilizing neutrophils. We believe that the research team established through this collaboration will lead to the discovery of the next generation of immunotherapy with us".
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
About Ono
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/en.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
View the original press release on newswire.com.
SOURCE: BioMed X Institute
To view this piece of content from stats.newswire.com, please give your consent at the top of this page. To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Maxon Announces Free Tools and Mobile Expansion of ZBrush and Cinema 4D16.4.2026 16:55:00 CEST | Press release
Cinema 4D brings professional 3D workflows to iPad. The return of Autograph - now free for individual users. ZBrush expands to Windows on Arm. See it all at NAB 2026. BAD HOMBURG, GERMANY / ACCESS Newswire / April 16, 2026 / Maxon, a leading developer of powerful and intuitive 2D and 3D software and complete graphic design workflows, today announced a major step forward in its mission to make professional creative tools more accessible to artists everywhere. With the debut of Cinema 4D on iPad, the return of the Autograph motion graphics application, and the expansion of Maxon tools to Windows on Arm (WoA) tablet devices, Maxon is lowering the barrier to entry while empowering artists to work where they want, how they want. Visitors to NAB 2026 can see it all at the Maxon booth (N2741). Professional Tools, Broader Access As demand for 3D and motion content accelerates across social media, streaming, gaming, and immersive media, creators are seeking flexible and affordable entry points
Maxon Announces Free Tools and Mobile Expansion of ZBrush and Cinema 4D16.4.2026 16:55:00 CEST | Press release
Cinema 4D brings professional 3D workflows to iPad. The return of Autograph - now free for individual users. ZBrush expands to Windows on Arm. See it all at NAB 2026. BAD HOMBURG, GERMANY / ACCESS Newswire / April 16, 2026 / Maxon, a leading developer of powerful and intuitive 2D and 3D software and complete graphic design workflows, today announced a major step forward in its mission to make professional creative tools more accessible to artists everywhere. With the debut of Cinema 4D on iPad, the return of the Autograph motion graphics application, and the expansion of Maxon tools to Windows on Arm (WoA) tablet devices, Maxon is lowering the barrier to entry while empowering artists to work where they want, how they want. Visitors to NAB 2026 can see it all at the Maxon booth (N2741). Professional Tools, Broader Access As demand for 3D and motion content accelerates across social media, streaming, gaming, and immersive media, creators are seeking flexible and affordable entry points
Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 202616.4.2026 15:20:00 CEST | Press release
Built on Available Infrastructure's SanQtum AI quantum-resistant edge platform, the 48,000-GPU fleet targets enterprises facing extended GPU lead times - with DataValue®, DataScore®, and Information Data Exchange® (IDE®) tokenization built in PHILADELPHIA, PA / ACCESS Newswire / April 16, 2026 / The global AI compute shortage has forced enterprises outside the hyperscaler customer set to wait extended periods for high-performance GPU capacity. Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the first sites of its new quantum-ready high-performance computing ("HPC") GPU network are now live in New York and Philadelphia, with commercial availability of the full 48,000-GPU fleet beginning in Q3 2026. The fleet will be distributed across 1,000 urban micro-edge neocloud sites in more than 100 U.S. cities by the end of 2026. Each
Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 202616.4.2026 15:20:00 CEST | Press release
Built on Available Infrastructure's SanQtum AI quantum-resistant edge platform, the 48,000-GPU fleet targets enterprises facing extended GPU lead times - with DataValue®, DataScore®, and Information Data Exchange® (IDE®) tokenization built in PHILADELPHIA, PA / ACCESS Newswire / April 16, 2026 / The global AI compute shortage has forced enterprises outside the hyperscaler customer set to wait extended periods for high-performance GPU capacity. Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the first sites of its new quantum-ready high-performance computing ("HPC") GPU network are now live in New York and Philadelphia, with commercial availability of the full 48,000-GPU fleet beginning in Q3 2026. The fleet will be distributed across 1,000 urban micro-edge neocloud sites in more than 100 U.S. cities by the end of 2026. Each
Camino Corporation Commences Drilling at Costa de Cobre District-Scale IOCG Copper Discovery in Peru16.4.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / April 16, 2026 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased to announce the commencement of a drilling campaign at its Costa de Cobre district-scale IOCG copper discovery in Peru ("Costa de Cobre" or "Copper Coast"), previously referred to as the Los Chapitos copper project(1). Camino has rebranded the Los Chapitos project as the Costa de Cobre, the Copper Coast, to better reflect its low-elevation coastal setting and strategic proximity to key infrastructure, including the proposed San Juan de Marcona Port Terminal, a major new port facility planned approximately 125 km to the north at Marcona. The Costa de Cobre project is advancing to the next stage of exploration and development as the Company enters into a joint venture with Nittetsu Mining Co., Ltd.("Nittetsu"), under which Camino will serve as operator and hold a 65% interest, while Nittetsu will hold the remaining 35% interest. Camino is also d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom